USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended December 30, 2023.
Key Financial Results & Guidance:

Fourth quarter net sales were $221 million versus $228 million during Q4 2022 and $213 million during Q3 2023.
Fourth quarter diluted EPS was $0.87 as compared with $0.66 during Q4 2022.
Fiscal year 2023 net sales were $921 million as compared with $999 million during fiscal year 2022.
Fiscal year 2023 diluted EPS totaled $3.30 versus $3.59 during fiscal year 2022.
Company provides initial fiscal year 2024 net sales and diluted EPS guidance of $850 million to $920 million and $2.40 to $3.00, respectively.

Jim Brown, President and Chief Executive Officer said:

“USANA delivered solid fourth quarter operating results, which exceeded our expectations. Our sales strengthened, in part, in response to a global incentive offering that was particularly effective in our Greater China region where it helped generate double-digit sequential growth in Active Customer counts.
This boost helped to offset the seasonal slowdown we typically experience during the final month of the quarter and helped us finish the year strong.”

Mr. Brown continued,
“Both net sales and diluted EPS for fiscal 2023 exceeded our guidance ranges. Although 2023 was a challenging

Read more...